Cardiology

Top Story

VIDEO: Optimal duration of DAPT a continued focus of research

August 31, 2015

LONDON — In this video, Deepak L. Bhatt, MD, MPH, Chief Medical Editor of Cardiology Today’s Intervention, discusses results of the OPTIDUAL Hot Line trial of dual antiplatelet therapy after drug-eluting stent implantation and provides his opinion on future research to determine the optimal duration of therapy in this population.

The OPTIDUAL trial did not demonstrate superiority of 48-month dual antiplatelet therapy (DAPT) compared with 12-month DAPT for the primary outcome of net adverse cardiac events, according to results presented here. However, post-hoc analysis of ischemic outcomes revealed a borderline but not statistically significant reduction with extended DAPT.

Gerard Helft Meeting News Coverage

OPTIDUAL: Extended DAPT not superior to 12-month therapy

August 31, 2015
LONDON — Extending dual antiplatelet therapy with clopidogrel and aspirin for 48 months was not superior to 12 months of therapy for the reduction of net adverse…
VIDEO: SCOT study addresses CV risk conferred by NSAIDs Meeting News CoverageVideo

VIDEO: SCOT study addresses CV risk conferred by NSAIDs

August 31, 2015
LONDON — In this video, Richard A. Chazal, MD, FACC, medical director of the Heart and Vascular Institute at Lee Memorial Health System, Fort Myers, Florida, and…
Bryan Williams Meeting News CoveragePerspective

PATHWAY-2: Spironolactone benefits patients with resistant hypertension

August 31, 2015
LONDON — In patients with resistant hypertension despite guideline-directed medical therapy, the addition of spironolactone produced a greater reduction in BP than…
In the Journals

Diabetes, depression predict poor survival, rehospitalization in patients with heart failure

August 31, 2015
Poorer survival and rehospitalization in patients with heart failure are associated with comorbid diabetes and depressive symptoms, according to recent study findings…
More News Headlines »
CME
Highlights from Lipid Forum 2015™: Focus on Hypertriglyceridemia

Highlights from Lipid Forum 2015®: Focus on Hypertriglyceridemia

This activity is supported by an educational grant from AstraZeneca.

Hypertriglyceridemia is a highly prevalent yet modifiable risk factor for atherosclerotic disease, pancreatitis, and…
More »
Meeting News Coverage Video
VIDEO: SCOT study addresses CV risk conferred by NSAIDs

VIDEO: SCOT study addresses CV risk conferred by NSAIDs

August 31, 2015
LONDON — In this video, Richard A. Chazal, MD, FACC, medical director of the Heart and Vascular Institute at Lee…
More »
CME
Spotlight on Hypercholesterolemia: New Ways to Test and Treat

Spotlight on Hypercholesterolemia: New Ways to Test and Treat

This activity is supported by an educational grant from Synageva BioPharma Corp.

Hereditary dyslipidemias are caused by single or multiple gene mutations that result in either overproduction or…
More »